# News

## News Articles

### July 2, 2026
**Evidation Insights from 165,000 People Show Continued Growth Potential Amid Uneven Adoption in the GLP-1 Market**  
[Read more](https://press@evidation.com/resources/growth-potential-and-uneven-adoption-in-the-glp-1-market)  
_Among 119,000 surveyed individuals actively trying to lose weight, 24% had ever used prescription medication for weight management and 15% had ever used a GLP-1, suggesting significant room for continued market growth as adoption varies by age, gender, and income._

### March 26, 2026
**Evidation Launches Interactive Dermatology Cohort; Shares Preliminary Real-World Insights**  
[Read more](https://press@evidation.com/resources/evidation-launches-interactive-dermatology-cohort)  
_New cohort is designed to address gaps in understanding treatment journeys across the full continuum of care. Insights show that consumer health products play a critical part in how individuals understand and manage their skin conditions._

### October 17, 2024
**Evidation partners with 1upHealth to integrate diverse sources of permissioned real-world health data for research**  
[Read more](https://press@evidation.com/resources/evidation-partners-with-1uphealth-to-integrate-diverse-sources-of-permissioned-real-world-health-data-for-research)  
_Evidation and 1upHealth announce a long-term partnership to advance patient-centered, real-world health research._

### January 8, 2026
**Evidation Launches Temporal Proteomics Platform to Power Autoimmune Research**  
[Read more](https://press@evidation.com/resources/evidation-launches-temporal-proteomics-platform-and-autoimmune-cohort)  
_New AI-enabled data collection platform will drive the development of novel multimodal datasets for biomarker discovery, treatment-response modeling, and foundation models of the immune system._

### December 16, 2025
**‍Evidation Shares Insights on Real-World GLP-1 Dosing Behaviors from Over 60,000 Individuals**  
[Read more](https://press@evidation.com/resources/real-world-glp-1-dosing-behaviors)  
_New insights from Evidation’s cardiometabolic health and weight management cohort show what factors shape real-world dosing decisions._

### April 1, 2026
**Evidation Appoints Dr. Ghazanfar Khan as Chief Medical Officer**  
[Read more](https://press@evidation.com/resources/evidation-appoints-dr-ghazanfar-khan-as-chief-medical-officer)  
_Evidation appoints Dr. Ghazanfar Khan as Chief Medical Officer._

### March 6, 2025
**Evidation Appoints Leslie Oley Wilberforce as CEO**  
[Read more](https://press@evidation.com/resources/evidation-appoints-leslie-oley-wilberforce-as-ceo)  
_Evidation appoints Leslie Oley Wilberforce as CEO. Wilberforce will lead Evidation’s next phase of growth in interactive real-world data and health research._

### October 3, 2024
**Evidation appoints Phil Johnson as Chief Commercial Officer**  
[Read more](https://press@evidation.com/resources/evidation-appoints-phil-johnson-as-chief-commercial-officer)  
_Evidation announces the addition of a new Chief Commercial Officer, Phil Johnson._

### September 17, 2024
**Trialbee and Evidation partner to accelerate and diversify clinical research recruitment**  
[Read more](https://press@evidation.com/resources/trialbee-and-evidation-partner-to-accelerate-and-diversify-clinical-research-recruitment)  
_Learn how Evidation and Trialbee's joint offering drives enrollment outcomes._

### July 15, 2024
**Rock Health shares findings from weight care survey with Evidation**  
[Read more](https://press@evidation.com/resources/rock-health-shares-findings-from-weight-care-survey-with-evidation)  
_Evidation helped Rock Health conduct surveys that investigated experience and perceptions of a variety of weight care solutions._